

## Figure S6. Galunisertib or anti-PD-1 monotherapy fails to significantly improve survival in KPC mice

Pdx1-Cre x LSL-KRAS<sup>G12D</sup> x TP53<sup>R172H</sup> (KPC) mice were generated and treated as described. Survival was plotted by the Kaplan-Meier method, indicating no significant difference between Control, Galunisertib, or anti-PD-1 treated mice (N=4-9/ group).